Imatinib for relapsed BCR/ABL positive leukemias

Annals of Hematology

Volumn 81, Issue SUPPL. 2, 2002, Pages

  Ottmann, O G ^a   Wassmann, B ^a   Hoelzer, D ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL STUDY; DATA ANALYSIS; DIARRHEA; DRUG MECHANISM; DRUG RESPONSE; FACE EDEMA; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; LEG EDEMA; LEUKEMIA; LEUKEMIA REMISSION; LEUKOPENIA; MINIMAL RESIDUAL DISEASE; MUSCLE CRAMP; PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; PRIORITY JOURNAL; RASH; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; PHILADELPHIA CHROMOSOME; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; STEM CELL TRANSPLANTATION;

EID: 0036989987     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Cornelissen JJ, Carston M, Kollman C, et al. (2001) Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 97:1572-1577.
2. Deininger MW, Goldman JM, Lydon N, and Melo JV (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90:3691-3698.
3. Druker BJ, Talpaz M, Resta DJ, et al. (2001a) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N.Engl.J.Med 344:1031-1037.
4. Druker BJ, Sawyers CL, Kantarjian H, et al. (2001b) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N.Engl.J.Med 344:1038-1042.
5. Gleißner, B, Gökbuget, N, Bartram, CR, et al. (2002) Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99:1536-1543.
6. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, and Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531):876-880.
7. Hofmann WK, de Vos S, Elashoff D, Gschaidmeier H., Hoelzer D, Koeffler HP, and Ottmann, OG (2002a) Relation between resistance of Philadelphia-chromosome positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 359:481-486.
8. Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D, Ottmann OG, and Koeffler HP (2002b) Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99:1860-1862.
9. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, and Melo JV (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96(3):1070-1079.
10. Martin TG and Gajewski JL (2001) Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. In: Kantarjian HM, Hoelzer D, Larson RA, eds. Advances in the treatment of adult acute lymphocytic leukemia, Part 2; Hematology/Oncology Clinics of North America. Saunders, Philadelphia PA 15:97-120.
11. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger M, Schiffer CA, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes-Reese S, Gathmann I, Capdeville R, and O'Brien SG (2002) A phase II study of Imatinib Mesylate (Glivec™) in Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoid Leukemias. Blood (in press)
12. Radich JP (2001) Philadelphia chromosome-positive acute lymphocytic leukemia. In: Kantarjian HM, Hoelzer D, Larson RA, eds. Advances in the treatment of adult acute lymphocytic leukemia, Part 2; Hematology/Oncology Clinics of North America. Saunders, Philadelphia PA; 15:21-36.
13. Sawyers CL, Hochhaus A, Silver RT, Goldman JM, Miller C, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Niederwieser D, Fischer T, O'Brien SG, Stone R, Corneo G, Russell N, Reiffers J, Shea T, Chapuis B, Coutre S, Tura S; Morra E, Larsen R, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, and Druker B (2002) Glivec™ (imatinib mesylate) Induces Hematologic and Cytogenetic Responses in Patients with Chronic Myeloid Leukemia in Myeloid Blast Crisis: Results of a Phase II Study. Blood 99:3530-3539
14. Talpaz M, Silver RT, Druker BJ, et al. (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood;99:1928-1937
15. von Bubnoff N, Schneller F, Peschel C, and Duyster J (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359:487-491.